The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry. While biologics like dupilumab have already transformed care, ...

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...